The IMPACT system offers users the ability to produce various autologous blood products using just one platform. Autologous blood products – internationally known as orthobiologics – utilize the body’s own regenerative mechanisms.
One system – numerous therapy options
With the IMPACT system, a wide range of autologous cell therapies can be offered. This allows for even more targeted responses to the individual therapeutic needs of patients. Autologous cell therapies harness the body’s natural mechanisms for the regeneration and healing of injured tissue.
Superior handling
- Fully automated system
- Therapy preparation: fast and easy
- Therapy is immediately ready to use
Top results with high reproducibility 1
- High platelet yield
- High yield of growth factors and anti-inflammatory cytokines
- Presence or absence of leukocytes can be determined by the user
- 1 Scientifically verified serum concentrations (TU Munich)
High flexibility
- One system for a wide range of autologous cell therapies
- Storage option for custom program variants
- Suitable for both clinic and operating room use
Excellent safety
- Closed system
- Scientifically validated IMPACT programs
- Reliability and quality made in Germany
One system – numerous therapy options
The IMPACT system offers users the ability to produce various autologous blood products using just one platform. Autologous blood products – internationally known as orthobiologics – utilize the body’s own regenerative mechanisms. They contain, for example, growth factors, anti-inflammatory cytokines, or stem cells in concentrated form. After being injected into the defect area, these support the body in the natural healing of injured tissue. The innovative IMPACT technology enables variable concentrations of leukocytes and platelets.
And all of this with a very simple, automated preparation process. For the different compositions of autologous therapies, IMPACT programs with specific, scientifically validated parameters are recommended. The system also allows users to create and store their own program variants.
With the IMPACT system, a wide range of autologous cell therapies can be offered. This allows for even more targeted responses to the individual therapeutic needs of patients.
EASY HANDLING
Reliable technology for reproducible results
With IMPACT, centrifugation and separation of the desired blood fractions take place fully automatically in a closed system. The built-in optical sensor can be adjusted in sensitivity and separates reliably and precisely. The syringe containing the patient’s blood is inserted, and once the program is complete, the desired autologous blood product is removed “ready-to-use.”
Technical data
Dimensions (H x W x D): 456 x 555 x 707 mm
Capacity: 2 x 12 ml
Max. RPM: 2,800
Max. RCF: 940
Operation via intuitive, user-friendly touch display
Innovative Technologie
Innovative and customizable production of AUTOLOGOUS, i.e., PATIENT-DERIVED CELL THERAPIES – with just one system
With the IMPACT system, a wide variety of autologous cell therapies can be produced at the push of a button. The selection is made depending on the specific therapeutic goal. Ready-to-use IMPACT sets with the corresponding consumables are available for the production of different therapeutic applications:
IMPACT PRP – Platelet Rich Plasma
without anticoagulant for the production of lightly concentrated platelet-rich plasma
IMPACT APC – Autologous Platelet Concentrate
with anticoagulant for the production of a highly concentrated platelet concentrate
IMPACT ACS – Autologous Conditioned Serum
for the production of autologous conditioned serum
Additional IMPACT sets in preparation
